Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for May 5th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th:

Zynex, Inc. (ZYXI - Free Report) : This company that designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.3% over the last 60 days.

Zynex Inc. Price and Consensus

Zynex Inc. Price and Consensus

Zynex Inc. price-consensus-chart | Zynex Inc. Quote

Zynex’s shares gained 84.1% over the last one month compared with the S&P 500 growth 15.7%. The company possesses a Momentum Score of A.

Pluralsight, Inc. (PS - Free Report) : This company that provides a technology skill development solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.4% over the last 60 days.

Pluralsight’s shares gained 58.5% over the last one month. The company possesses a Momentum Score of A.

Gold Fields Limited (GFI - Free Report) : This company that operates as a gold producer with reserves and resources has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.

Gold Fields’ shares gained 47.4% over the last one month. The company possesses a Momentum Score of A.

Axovant Gene Therapies Ltd. (AXGT - Free Report) : This clinical-stage gene therapy company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.

Axovant Gene Therapies’ shares gained 28.1% over the last one month. The company possesses a Momentum Score of A.

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Zynex Inc. (ZYXI) - free report >>

Pluralsight, Inc. (PS) - free report >>

Gold Fields Limited (GFI) - free report >>

Axovant Sciences Ltd. (AXGT) - free report >>

Published in